Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Mobilization of Stem Cells with AMD3100 in Non-Hodgkin’s Lymphoma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 78				Pharmaceutical / Industry				AMD3100-3101 NCT00103610


2.		Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 65				Other				03-0349 NCT00241358


3.		Study of AMD3100 and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 80				Pharmaceutical / Industry				MOZO00207 NCT00694590


4.		AMD3100 + G-CSF Mobilization for Autologous Transplant for Patients With Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Approved-not yet active				18 to 75				Other				08-X177 NCT00733824


5.		AMD3100 With Mitoxantrone, Etoposide and Cytarabine in Relapsed or Refractory AML

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				07-0227 NCT00512252


6.		AMD3100 With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed HSC Collection/Attempts

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 78				Pharmaceutical / Industry				AMD3100-2112 NCT00396331


7.		Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM), Who Have Failed Previous Mobilization

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Active				18 to 78				Pharmaceutical / Industry				AMD3100-EU23 EudraCT number: 2006-00424729, NCT00665314


8.		Safety Study of AMD3100 With G-CSF to Increase Peripheral Blood Stem Cells

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Supportive care				Active				18 to 70				Pharmaceutical / Industry				H-18743 NCT00291811


9.		Long-Term Follow Up Study for AMD3100 Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Active				18 to 78				Other				2006-0665 NCT00476294

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute